{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086535","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.888177+00:00","generated_at":"2026-05-31T11:40:14.209893+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocular Therapeutix Q2 net loss $(43.8)M; AXPAXLI SOL-R accepted as pivotal trial","bullets":["Net loss of $(43.8)M ($(0.26)/share) vs $(20.7)M ($(0.26)/share) in Q2 2023; revenue $16.4M (+8.3% YoY).","Cash $459.7M as of June 30, 2024; expected to fund operations into 2028.","FDA confirmed SOL-R repeat dosing study (Phase 3 wet AMD) is appropriate as second registrational trial; ~825 subjects to be randomized.","SOL-1 enrollment accelerating: 151 subjects enrolled as of June 7, 2024, 60 active sites.","HELIOS Phase 1 NPDR data showed DRSS improvement; no intraocular inflammation; presented at ASRS."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086535","json":"https://secwatch.observer/filing/0001104659-24-086535.json","markdown":"https://secwatch.observer/filing/0001104659-24-086535.md","text":"https://secwatch.observer/filing/0001104659-24-086535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924086535/0001104659-24-086535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924086535/tm2420962d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:40:14.209893+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}